NIH-Funding

Notice of Expiration of PAR-16-340 "Career Transition Award for NINDS Intramural Clinician-Scientists (K22)"

NIH Funding Announcements - Thu, 01/11/2018 - 11:59
Notice NOT-NS-18-035 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Expiration of PAR-15-195 "NeuroNEXT Infrastructure Resource Access (X01)"

NIH Funding Announcements - Thu, 01/11/2018 - 10:30
Notice NOT-NS-18-037 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Tue, 01/09/2018 - 15:39

Your application would have been discussed internally at NIDDK, not at the Council meeting (Council only discusses applications with controversial reviews and a few other special instances). Council would have approved your application to be considered for funding, and then the NIDDK leadership needed to decide which applications to fund based both on score and programmatic interest. I am a little unclear as to what you are saying happened, but it sounds as though your application was not selected for special pay (above payline), which means you will need to submit an A1 application in March (or next July). If that is the case, you will want to work with your PO to be sure your amended application addresses NIDDK priorities in the manner of most interest to them, if you can make adjustments that improve how the NIDDK leadership views your proposal (your PO will know whether you can make any such adjustments). You have already addressed the reviewer critiques (for NIDDK) – you can also ask if the rebuttal you prepared for your PO can be used for the A1 application (PO also would have attended the study section meeting & heard the discussion of your application).

Categories: NIH-Funding

By: SaG

WriteEdit-Grant Questions Blog - Tue, 01/09/2018 - 14:21

It isn’t uncommon for PARs to only have 1 or 2 submission dates per year. My guess it that they didn’t want these to go to the first Council of the Fiscal Year (October).

Categories: NIH-Funding

Cutting-Edge Basic Research Awards (CEBRA) (R21-Clinical Trial Optional)

NIH Funding Announcements - Tue, 01/09/2018 - 13:30
Funding Opportunity PAR-18-437 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio. The proposed research should: (1) test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking; and/or (2) develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research.
Categories: NIH-Funding

Hearing Health Care for Adults: Improving Access and Affordability (R01 Clinical Trial Optional)

NIH Funding Announcements - Tue, 01/09/2018 - 13:07
Funding Opportunity PA-18-438 from the NIH Guide for Grants and Contracts. This FOA encourages applications for research on hearing health care in adults in support of improving access and affordability. Further research is needed to strengthen the evidence base with a goal of delivering better hearing health care outcomes in adults.
Categories: NIH-Funding

Hearing Health Care for Adults: Improving Access and Affordability (R21 Clinical Trial Optional)

NIH Funding Announcements - Tue, 01/09/2018 - 13:07
Funding Opportunity PA-18-382 from the NIH Guide for Grants and Contracts. This FOA encourages exploratory and developmental research applications for research on hearing health care in adults in support of improving access and affordability. Further research is needed to strengthen the evidence base with a goal of delivering better health care outcomes in adults.
Categories: NIH-Funding